NOVARTIS MOVES CHENNAI HC AGAINST INVALIDATION OF GLIVEC PATENT

Novartis India has approached Chennai High Court against the orders of the Patent Controller invalidating the patent claim on Novartis' block buster anti-cancer drug Glivec (Imatinib Mesvlate). The company has questioned the constitutional validity of Section 3(d) of the Patents Act 1970 itself and has pleaded that any decision considered under Section 3 (d) should be considered legally non-tenable. The HC has issued notices to all respondents and has called for a hearing on August 23. Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=34678ionid=)